PT3390390T - Derivados de bipirazolilo úteis para o tratamento de doenças autoimunes - Google Patents

Derivados de bipirazolilo úteis para o tratamento de doenças autoimunes

Info

Publication number
PT3390390T
PT3390390T PT168673788T PT16867378T PT3390390T PT 3390390 T PT3390390 T PT 3390390T PT 168673788 T PT168673788 T PT 168673788T PT 16867378 T PT16867378 T PT 16867378T PT 3390390 T PT3390390 T PT 3390390T
Authority
PT
Portugal
Prior art keywords
bipyrazolyl
treatment
autoimmune diseases
derivatives useful
derivatives
Prior art date
Application number
PT168673788T
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PT3390390T publication Critical patent/PT3390390T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
PT168673788T 2015-12-16 2016-12-15 Derivados de bipirazolilo úteis para o tratamento de doenças autoimunes PT3390390T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268278P 2015-12-16 2015-12-16
US201662431008P 2016-12-07 2016-12-07

Publications (1)

Publication Number Publication Date
PT3390390T true PT3390390T (pt) 2021-11-18

Family

ID=58737849

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168673788T PT3390390T (pt) 2015-12-16 2016-12-15 Derivados de bipirazolilo úteis para o tratamento de doenças autoimunes

Country Status (31)

Country Link
US (6) US9975882B2 (pt)
EP (1) EP3390390B1 (pt)
JP (1) JP6976947B2 (pt)
KR (1) KR20180095655A (pt)
CN (1) CN108368086B (pt)
AU (1) AU2016370743B2 (pt)
BR (1) BR112018011969B1 (pt)
CA (1) CA3005268C (pt)
CL (1) CL2018001569A1 (pt)
CO (1) CO2018005954A2 (pt)
CY (1) CY1124749T1 (pt)
DK (1) DK3390390T3 (pt)
EA (1) EA034561B1 (pt)
ES (1) ES2897910T3 (pt)
HK (1) HK1256795A1 (pt)
HR (1) HRP20211845T1 (pt)
HU (1) HUE056877T2 (pt)
IL (1) IL259281B (pt)
LT (1) LT3390390T (pt)
MX (1) MX2018007333A (pt)
MY (1) MY197440A (pt)
PE (1) PE20181074A1 (pt)
PH (1) PH12018501248A1 (pt)
PL (1) PL3390390T3 (pt)
PT (1) PT3390390T (pt)
RS (1) RS62525B1 (pt)
SA (1) SA518391864B1 (pt)
SG (1) SG11201804890TA (pt)
SI (1) SI3390390T1 (pt)
TW (1) TWI726017B (pt)
WO (1) WO2017106429A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882741B1 (en) 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
PL3390390T3 (pl) * 2015-12-16 2022-01-24 Boehringer Ingelheim International Gmbh Pochodne bipirazolilu przydatne w leczeniu chorób autoimmunologicznych
EP3390395B1 (en) 2015-12-16 2020-09-09 Loxo Oncology, Inc. Compounds useful as kinase inhibitors
JP6916185B2 (ja) 2016-01-13 2021-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Btk阻害剤としてのイソキノロン類
EP3661939B1 (en) * 2017-08-01 2021-07-21 Boehringer Ingelheim International GmbH Intermediate compounds and methods
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2022533968A (ja) * 2019-05-23 2022-07-27 ノバルティス アーゲー ブルトン型チロシンキナーゼ阻害剤を使用したシェーグレン症候群を処置する方法
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
AU782878B2 (en) * 2000-02-05 2005-09-08 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
EA007933B1 (ru) 2001-08-13 2007-02-27 Янссен Фармацевтика Н.В. 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность
US7307097B2 (en) 2001-09-27 2007-12-11 Smithkline Beechman Corporation Chemical compounds
FR2881426B1 (fr) 2005-02-03 2007-03-30 Aventis Pharma Sa Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation
EP2007732B1 (en) 2006-04-11 2011-11-23 Vertex Pharmaceuticals, Inc. Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
CA2874756C (en) 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
DK2310528T3 (da) 2008-07-29 2013-12-02 Univ Liege Genetisk markør-test til brachyspina og frugtbarhed hos kvæg
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
WO2011082732A1 (de) 2009-12-17 2011-07-14 Merck Patent Gmbh Inhibitoren der sphingosinkinase
EP2578585B1 (en) 2010-05-31 2016-07-20 ONO Pharmaceutical Co., Ltd. Purinone derivative as btk kinase inhibitor
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2809673B1 (en) * 2012-01-31 2016-11-02 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as bruton's tyrosine kinase inhibitors
EP2882741B1 (en) 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
US20150291554A1 (en) 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
EP2970163B1 (en) * 2013-03-14 2018-02-28 Boehringer Ingelheim International GmbH 5-thiazolecarboxamide dervatives and their use as btk inhibitors
WO2015116485A1 (en) * 2014-01-29 2015-08-06 Boehringer Ingelheim International Gmbh Pyrazole compounds as btk inhibitors
PL3390390T3 (pl) * 2015-12-16 2022-01-24 Boehringer Ingelheim International Gmbh Pochodne bipirazolilu przydatne w leczeniu chorób autoimmunologicznych

Also Published As

Publication number Publication date
EP3390390B1 (en) 2021-09-01
HRP20211845T1 (hr) 2022-03-04
EP3390390A2 (en) 2018-10-24
MY197440A (en) 2023-06-19
WO2017106429A2 (en) 2017-06-22
US20190092759A1 (en) 2019-03-28
US20170174663A1 (en) 2017-06-22
CN108368086A (zh) 2018-08-03
MX2018007333A (es) 2018-08-24
SA518391864B1 (ar) 2021-12-13
US20200055843A1 (en) 2020-02-20
DK3390390T3 (da) 2021-12-06
ES2897910T3 (es) 2022-03-03
WO2017106429A3 (en) 2017-08-17
AU2016370743A1 (en) 2018-05-24
RS62525B1 (sr) 2021-11-30
HK1256795A1 (zh) 2019-10-04
CA3005268C (en) 2024-04-30
US20180030037A1 (en) 2018-02-01
CA3005268A1 (en) 2017-06-22
PH12018501248A1 (en) 2019-01-28
CY1124749T1 (el) 2022-07-22
CN108368086B (zh) 2021-01-08
KR20180095655A (ko) 2018-08-27
AU2016370743B2 (en) 2020-11-26
CO2018005954A2 (es) 2018-07-10
JP6976947B2 (ja) 2021-12-08
TW201731838A (zh) 2017-09-16
HUE056877T2 (hu) 2022-03-28
TWI726017B (zh) 2021-05-01
CL2018001569A1 (es) 2018-10-05
BR112018011969B1 (pt) 2023-02-23
IL259281B (en) 2021-04-29
PL3390390T3 (pl) 2022-01-24
JP2019505491A (ja) 2019-02-28
SG11201804890TA (en) 2018-07-30
SI3390390T1 (sl) 2021-12-31
BR112018011969A2 (pt) 2018-12-04
EA201891399A1 (ru) 2019-01-31
PE20181074A1 (es) 2018-07-04
US20180222893A1 (en) 2018-08-09
LT3390390T (lt) 2021-11-25
IL259281A (en) 2018-07-31
US9975882B2 (en) 2018-05-22
EA034561B1 (ru) 2020-02-20
US20210009567A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
HK1256795A1 (zh) 可用於治療自身免疫疾病的二吡唑基衍生物
IL253945B (en) kdm1a inhibitors to treat the disease
EP3227330C0 (en) TDP-43 BINDING POLYPEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
PT3169328T (pt) Derivados de quinolina para o tratamento de doenças inflamatórias
HK1244485A1 (zh) 用於治療神經母細胞瘤的組合物
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
HK1232220A1 (zh) 用於治療心血管疾病的 -苄基異喹啉衍生物
HK1258994A1 (zh) 用於疾病治療的方法
GB201417163D0 (en) Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
EP3145931A4 (en) Treatment of autoimmune disease
PL3129483T3 (pl) Terapia skojarzona do leczenia chorób autoimmunologicznych
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
EP3096775A4 (en) Socs mimetics for the treatment of diseases
EP3376869A4 (en) AUTOIMMUNE DISEASE TREATMENT
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
IL259381B (en) Miravegron for the treatment of retinal diseases
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
IL272422A (en) Methods for treating diseases of the meninges
GB201514909D0 (en) Treatment of autoimmune diseases
GB201504413D0 (en) Treatment of disease
GB201414023D0 (en) Treatment of autoimmune diseases